Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) General Information
Description
Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920 gene therapy asset.
Contact Information
Corporate Office
- Richmond, CA
- United States
Corporate Office
- Richmond, CA
- United States
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) FAQs
-
Where is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) headquartered?
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is headquartered in Richmond, CA.
-
What industry is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) in?
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)’s primary industry is Buildings and Property.
-
Is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) a private or public company?
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is a Private company.
-
What is the current valuation of Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)?
The current valuation of Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is .
-
What is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)’s current revenue?
The current revenue for Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is .
-
Who are Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)’s investors?
Sangamo Therapeutics has invested in Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920).
-
When was Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) acquired?
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) was acquired on 21-Sep-2026.
-
Who acquired Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)?
Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) was acquired by PTC Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process